Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Treatment Strategy: The Path to a Cure

At a Glance

The primary and most effective treatment for Unicentric Castleman Disease (UCD) is complete surgical removal of the affected lymph node, which is curative in up to 95% of cases. If the mass cannot be safely removed, treatments include observation, radiation, or targeted medications like siltuximab.

The primary goal of treatment for Unicentric Castleman Disease (UCD) is the complete removal of the affected lymph node or mass. Because UCD is a localized condition, achieving a complete surgical resection (removing the entire mass with “clear margins”) is the gold standard and is often curative [1][2].

The Treatment Decision Tree

Doctors generally follow a standard path when deciding how to manage UCD:

  1. Assessment of Resectability: The first step is determining if the mass can be safely removed without damaging vital structures like major blood vessels or nerves [1].
  2. Symptom Check: The presence of systemic inflammatory symptoms (like fever, anemia, or weight loss) may influence whether medical therapy is needed before or instead of surgery [3][4].

Surgical Options (The Gold Standard)

If the mass is resectable, surgery is the first-line treatment [5][6].

  • Curative Intent: For the vast majority of patients, surgery is the only treatment needed, with cure rates reported as high as 95% [7][8].
  • Minimally Invasive vs. Open Surgery: Depending on the size and location of the mass, surgeons may use laparoscopic (in the abdomen) or Video-Assisted Thoracoscopic Surgery (VATS) (in the chest) techniques [9][10]. These minimally invasive approaches typically offer shorter hospital stays and faster recovery times than traditional open surgery [9][11].
  • A Note on Vascularity: UCD masses are often “hypervascular,” meaning they have a dense network of blood vessels [12]. Surgeons must be careful to manage potential bleeding during the procedure [13].

What to Expect from Surgery and Recovery

While surgery for UCD is highly successful, it is still a major procedure. Your specific recovery timeline will depend heavily on the surgical approach:

  • Hospital Stay: Minimally invasive surgeries usually require a 1 to 3-day hospital stay. Open surgeries, particularly in the chest or abdomen, may require 3 to 7 days in the hospital for monitoring.
  • Pain Management: You will likely experience localized pain, soreness, and fatigue for the first few weeks, which your care team will help manage with medication.
  • Physical Restrictions: You will generally be advised not to lift heavy objects (typically anything over 10 pounds) or engage in strenuous exercise for 4 to 6 weeks to allow internal tissues to heal properly.

Options for Unresectable UCD

In cases where a mass is too close to critical organs or nerves to be safely removed, or if the patient is too ill for surgery, other options are available:

  • Observation (Watch and Wait): If the mass cannot be safely removed but is not causing any symptoms or organ damage, the standard of care is often active monitoring. Your doctor will track the mass with periodic scans rather than intervening with harsh medications or radiation [1][3].
  • Anti-IL-6 Therapy (Siltuximab): This is a targeted monoclonal antibody that blocks interleukin-6 (IL-6), a protein that drives inflammation. It is particularly useful for patients with the plasmacytic variant who have systemic symptoms [3][14].
  • Corticosteroids: Medications like prednisone may be used to quickly reduce systemic inflammation, often as a bridge alongside other therapies [14].
  • Radiotherapy (Radiation): Radiation can be used to shrink the mass and achieve disease control in patients who cannot have surgery [15][16].
  • Embolization: This procedure involves blocking the blood flow to the tumor, which can shrink the mass or make it safer to remove surgically at a later date [17].
  • Rituximab: This medication targets B-cells and may be used as an adjunctive therapy, especially in rare cases where UCD is associated with paraneoplastic syndromes [18][19].

Next Steps:

Common questions in this guide

Is Unicentric Castleman Disease curable?
Yes, for the vast majority of patients, completely removing the affected lymph node through surgery is curative. Success rates for complete surgical resection are reported to be as high as 95%.
What happens if my UCD mass cannot be safely removed?
If the mass is located near vital organs or nerves and cannot be safely removed, your doctor may recommend a 'watch and wait' approach with periodic scans. Other options include radiation to shrink the mass or medications like siltuximab and corticosteroids.
What is the recovery time after Unicentric Castleman Disease surgery?
Recovery depends on the type of surgery you have. Minimally invasive procedures usually require a 1 to 3-day hospital stay, while open surgeries may require up to a week. Most patients are advised to avoid strenuous activity and heavy lifting for 4 to 6 weeks.
Why do doctors consider UCD surgery to be complex?
UCD masses are often hypervascular, meaning they contain a very dense network of blood vessels. This makes the tumor prone to bleeding during removal, so surgeons must take extra precautions to manage this risk safely.
Will I need medication or chemotherapy for Unicentric Castleman Disease?
Medications are generally reserved for patients whose tumor cannot be removed surgically, or those experiencing severe systemic symptoms like fever and weight loss. In those instances, doctors may prescribe targeted therapies like siltuximab or corticosteroids to reduce inflammation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.In your expert opinion, is my mass completely resectable with a clear margin?
  2. 2.Do you recommend a minimally invasive approach (laparoscopic or VATS) or an open surgery for my specific case?
  3. 3.How many UCD surgeries or highly vascular tumors have you performed?
  4. 4.If surgery is too high-risk, is a 'watch and wait' observation period appropriate for me, or should we consider systemic therapy?
  5. 5.What specific physical restrictions will I have during the first month of my recovery?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

    van Rhee F, Oksenhendler E, Srkalovic G, et al.

    Blood advances 2020; (4(23)):6039-6050 doi:10.1182/bloodadvances.2020003334.

    PMID: 33284946
  2. 2

    Complete resection of unicentric Castleman disease in the superior mediastinum: A case report.

    Haro A, Kuramitsu E, Fukuyama Y

    International journal of surgery case reports 2016; (25()):44-7.

    PMID: 27318017
  3. 3

    Unicentric Castlemans disease. Symptoms, diagnostics and therapy.

    Adam Z, Řehák Z, Adamová Z, et al.

    Vnitrni lekarstvi 2021; (67(8)):465-473.

    PMID: 35459366
  4. 4

    Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review.

    Fayand A, Boutboul D, Galicier L, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(4)):197-202 doi:10.1080/13506129.2019.1641078.

    PMID: 31364863
  5. 5

    Pelvic unicentric Castleman's disease mimicking accessory spleen: A rare presentation of Castleman's disease, a case report and literature report.

    Emiru ZA, Getahun AM, Kassie YG, et al.

    International journal of surgery case reports 2025; (129()):111177 doi:10.1016/j.ijscr.2025.111177.

    PMID: 40106952
  6. 6

    Unicentric Castleman disease with paraneoplastic pemphigus in a young woman: a case report.

    Lv GT, Zhao YH, Zhao JL, et al.

    Frontiers in medicine 2025; (12()):1749601 doi:10.3389/fmed.2025.1749601.

    PMID: 41625759
  7. 7

    Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases.

    Boutboul D, Fadlallah J, Chawki S, et al.

    British journal of haematology 2019; (186(2)):269-273 doi:10.1111/bjh.15921.

    PMID: 31016730
  8. 8

    Clinical features and management of head and neck castleman disease: a single-center retrospective analysis.

    Yang Y, Zhang X, Zhang Y, et al.

    Acta oto-laryngologica 2025; (145(9)):873-879 doi:10.1080/00016489.2025.2535436.

    PMID: 40694435
  9. 9

    Laparoscopic treatment of abdominal unicentric castleman's disease: a case report and literature review.

    Bracale U, Pacelli F, Milone M, et al.

    BMC surgery 2017; (17(1)):38 doi:10.1186/s12893-017-0238-6.

    PMID: 28403848
  10. 10

    Video-assisted thoracoscopic surgery is a safe and effective method to treat intrathoracic unicentric Castleman's disease.

    Wang YQ, Li SQ, Guo F

    BMC surgery 2020; (20(1)):127 doi:10.1186/s12893-020-00789-6.

    PMID: 32522182
  11. 11

    Mesenteric Vessel-Preserving Laparoscopic Surgery for Pediatric Unicentric Castleman Disease in the Transverse Mesocolon.

    Kobayashi T, Kinoshita Y, Takemoto J, et al.

    Surgical case reports 2025; (11(1)) doi:10.70352/scrj.cr.25-0307.

    PMID: 41080756
  12. 12

    Unicentric Castleman disease presenting as a longstanding axillary and chest wall mass: A case report.

    Zhou W, Liu X, Qiu A, et al.

    Clinical case reports 2023; (11(12)):e8258 doi:10.1002/ccr3.8258.

    PMID: 38054194
  13. 13

    Unicentric Castleman disease; the laparoscopic en bloc resection of a hypervascular giant lymph node in the aortacaval zone

    Erdem B, Karakış L, Asıcıoğlu O, et al.

    Journal of the Turkish German Gynecological Association 2021; (22(3)):259-261 doi:10.4274/jtgga.galenos.2020.2020.0092.

    PMID: 33631872
  14. 14

    [Unicentric Castleman disease: a blind lymph node.]

    Rizzi S, Polenzani I, Troisi A, et al.

    Recenti progressi in medicina 2021; (112(10)):653-658 doi:10.1701/3679.36656.

    PMID: 34647535
  15. 15

    The role of surgical resection in Unicentric Castleman's disease: a systematic review.

    Mitsos S, Stamatopoulos A, Patrini D, et al.

    Advances in respiratory medicine 2018; (86(1)):36-43 doi:10.5603/ARM.2018.0008.

    PMID: 29490420
  16. 16

    The Role of Radiation Therapy in Unicentric Castleman Disease: A Case Report.

    Rodriguez C, Rivera Rubi L, Menjivar O, Suazo J

    Cureus 2023; (15(11)):e49687 doi:10.7759/cureus.49687.

    PMID: 38161935
  17. 17

    Castleman disease: Report of a case and review of literature on role of preoperative embolization.

    Albesher MB, Alqahtani S, Alghamdi FR

    International journal of surgery case reports 2022; (95()):107222 doi:10.1016/j.ijscr.2022.107222.

    PMID: 35661495
  18. 18

    Unicentric Castleman disease-associated paraneoplastic pemphigus successfully managed with surgical resection and rituximab.

    Kaur S, Singh C, Bal A, Jain A

    BMJ case reports 2025; (18(2)) doi:10.1136/bcr-2024-263275.

    PMID: 40010754
  19. 19

    Clinical Analysis of Unicentric Castleman's Disease with Paraneoplastic Pemphigus and Bronchiolitis Obliterans.

    Zhen JF, Zhang L, Cao XX, et al.

    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2017; (39(4)):492-498 doi:10.3881/j.issn.1000-503X.2017.04.006.

    PMID: 28877826

This page explains Unicentric Castleman Disease treatment options for educational purposes only. Always consult your surgical team or oncologist to determine the safest and most effective treatment plan for your specific case.

Get notified when new evidence is published on Unicentric Castleman disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.